BMS-986310 clinical trials
Also written ONO-4578.
How each study uses BMS-986310 has had a first review. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the BMS-986310 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2017 (1); 1 more planned to start later
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2021 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Studies
Open first, then newest update. How each study uses BMS-986310 has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal AdenocarcinomaNot yet recruitingPhase 3Ono Pharmaceutical Co., Ltd.NCT07818070Written as ONO-4578Report a problem
- A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal CancerRecruitingPhase 2Ono Pharmaceutical Co., Ltd.NCT06948448Written as ONO-4578Report a problem
- An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung CancerCompletedPhase 1Ono Pharmaceutical Co., Ltd.NCT06542731Written as ONO-4578Report a problem
- Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid TumorsActive, not recruitingPhase 1Ono Pharmaceutical Co., Ltd.NCT03155061Written as ONO-4578Report a problem
- A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)Active, not recruitingPhase 2Ono Pharmaceutical Co., Ltd.NCT06256328Written as ONO-4578Report a problem
- An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid TumorsCompletedPhase 1Bristol-Myers SquibbNCT03661632Written as BMS-986310Report a problem
Tested with established drugs · 6 — they are given beside it
- A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal AdenocarcinomaNot yet recruitingPhase 3Ono Pharmaceutical Co., Ltd.NCT07818070Written as ONO-4578Report a problem
- A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal CancerRecruitingPhase 2Ono Pharmaceutical Co., Ltd.NCT06948448Written as ONO-4578Report a problem
- An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung CancerCompletedPhase 1Ono Pharmaceutical Co., Ltd.NCT06542731Written as ONO-4578Report a problem
- Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid TumorsActive, not recruitingPhase 1Ono Pharmaceutical Co., Ltd.NCT03155061Written as ONO-4578Report a problem
- A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)Active, not recruitingPhase 2Ono Pharmaceutical Co., Ltd.NCT06256328Written as ONO-4578Report a problem
- An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid TumorsCompletedPhase 1Bristol-Myers SquibbNCT03661632Written as BMS-986310Report a problem
Given beside what is tested · 3 — usual care or a partner of the new treatment
- Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal CancerActive, not recruitingPhase 1Ono Pharmaceutical Co., Ltd.NCT06547385In every armWritten as ONO-4578Report a problem
- ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast CancerCompletedPhase 1Ono Pharmaceutical Co., Ltd.NCT06570031In every armWritten as ONO-4578Report a problem
- An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic CancerCompletedPhase 1Ono Pharmaceutical Co. LtdNCT06538207In every armWritten as ONO-4578Report a problem
Codes
What other systems call BMS-986310 · ClinicalTrials.gg INT018251
- UNII (FDA) VJ3OXN6K2HBMS-986310One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | VJ3OXN6K2H | BMS-986310 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.